Core Viewpoint - The article highlights the recent funding activities of Kangai Medical, a leading provider of intelligent nutritional diagnosis and treatment solutions in China, and its commitment to enhancing nutritional support for patients, particularly in oncology [1][3]. Company Overview - Kangai Medical was established in 2011 and is headquartered in Huai'an, Jiangsu Province. The company focuses on providing comprehensive intelligent nutritional diagnosis solutions for medical institutions, with core products including intelligent screening systems, clinical nutritional testing devices, and a series of nutritional products [3]. - The mission of Kangai Medical is to improve the nutritional status of 160 million patients and accelerate their recovery [3]. Product and Technology - Kangai Medical's core products and technologies have significant advantages. The intelligent screening system enhances the efficiency of nutritional risk screening for patients, utilizing artificial intelligence software, automated devices, and standardized processes to simplify the nutritional diagnosis process, significantly improving screening accuracy and personalized treatment [4]. - The company has also launched the first clinical nutritional testing device in China, further enhancing its intelligent nutritional diagnosis solutions. These products and technologies have broad application prospects in the clinical nutrition field, effectively improving the nutritional diagnosis level of medical institutions and providing more precise and personalized nutritional support for patients [6]. Funding and Development Milestones - In July 2025, Kangai Medical completed a follow-on financing round of several million yuan, led by the state-owned fund of Huai'an, Jiangsu Province. The funds will primarily be used to accelerate the promotion and application of intelligent nutritional diagnosis solutions and deepen the layout in specialized medical food fields [1]. - The company has achieved several significant milestones, including the installation of nearly 200 devices in top hospitals across China and participation in multi-center clinical research [3][8].